Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 34Oropharyngeal Neoplasms 22Urinary Bladder Neoplasms 20Head and Neck Neoplasms 18Nasopharyngeal Carcinoma 17Carcinoma 15Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Squamous Cell Carcinoma 13Cholangiocarcinoma 13Colorectal Neoplasms 12Uterine Cervical Neoplasms 11Pancreatic Neoplasms 11Neoplasms 11Carcinoma, Squamous Cell 11Ovarian Neoplasms 10Mouth Neoplasms 9Laryngeal Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Mesothelioma, Malignant 6

Interventions

sodium thiosulfate 1ebselen 1Platinum 1Magnetic Resonance Spectroscopy 1Hearing Tests 1Hearing 1Cisplatin 1Atorvastatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hearing Loss × Cisplatin × 90 days × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡